Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Dec / Business-In-Brief
Business & Regulation Business Practice

Business-In-Brief

Criminal charges, drug pricing, and upgraded headquarters… What’s new in business?

12/18/2020 1 min read Quick Read (pre 2022)

Share

  • Purdue Pharma pleaded guilty to three charges concerning its role in the supply of OxyContin, bringing an end to its civil case with the US Department of Justice. The charges included two counts of conspiracy to violate the Federal Anti-Kickback Statute – a law that prevents the exchange of items or services for reward referrals – and one count of dual-object conspiracy to defraud the US.
  • Most Favoured Nation, a drug pricing policy, was set into motion in late November by President Donald Trump. The pricing model is expected to lower the cost of 50 prescription medicines in line with the prices paid by Europe’s wealthiest nations. The policy will come into effect on January 1, 2021.
  • In line with a new 15-year plan, Roche’s Genentech is expected to almost double its headquarters space to 9 million square feet. The upgraded sites will support the company’s R&D and manufacturing needs, and will accommodate an additional 12,000 members of staff.
  • A collaboration between Gavi, The Vaccine Alliance, and the International Organization for Migration pledges to provide vaccinations for those affected by emergency or humanitarian crises, and encourage companies to consider those who may otherwise be missed in their COVID-19 responses. “Children from migrant, refugee, and displaced populations are too often overlooked when it comes to basic health care. This obviously becomes all the more important as we plan to roll out COVID-19 vaccines worldwide; we cannot allow these populations to miss out on what could be one of our best routes out of this pandemic,” said Gavi’s CEO, Seth Berkley, in a statement.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.